Marvel Biosciences Corp. (TSXV:MRVL)

Market Cap	9.14M -32.2%
Revenue (ttm)	n/a
Net Income	-1.39M
EPS	-0.02
Shares Out	63.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,032
Open	0.1450
Previous Close	0.1450
Day's Range	0.1450 - 0.1450
52-Week Range	0.1150 - 0.2550
Beta	0.59
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 27, 2026

About Marvel Biosciences

Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: J. Matheson
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: MRVL

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 18, 2026

Data Sources Report a data error